| Metastatic castration-resistant prostate cancer
Jevtana vs Yonsa
Side-by-side clinical, coverage, and cost comparison for metastatic castration-resistant prostate cancer.Deep comparison between: Jevtana vs Yonsa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsYonsa has a higher rate of injection site reactions vs Jevtana based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Yonsa but not Jevtana, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Jevtana
Yonsa
At A Glance
IV infusion
Every 3 weeks
Microtubule inhibitor
Oral
Daily
CYP17 inhibitor
Indications
- Metastatic castration-resistant prostate cancer
- Metastatic castration-resistant prostate cancer
Dosing
Metastatic castration-resistant prostate cancer 20 mg/m2 as a one-hour IV infusion every three weeks in combination with oral prednisone 10 mg daily; 25 mg/m2 may be used in select patients at the discretion of the treating healthcare provider.
Metastatic castration-resistant prostate cancer 500 mg (four 125 mg tablets) orally once daily with or without food in combination with methylprednisolone 4 mg twice daily; concurrent GnRH analog or bilateral orchiectomy required.
Contraindications
- Neutrophil count <=1,500/mm3
- History of severe hypersensitivity reaction to cabazitaxel or to other drugs formulated with polysorbate 80
- Severe hepatic impairment (total bilirubin >3 x ULN)
—
Adverse Reactions
Most common (>=10%) Anemia, leukopenia, neutropenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, alopecia
Serious Neutropenia, leukopenia, anemia, febrile neutropenia, diarrhea, fatigue, asthenia
Postmarketing Gastritis, intestinal obstruction, interstitial pneumonia/pneumonitis, interstitial lung disease, acute respiratory distress syndrome, radiation recall hemorrhagic cystitis
Most common (>10%) Fatigue, joint swelling or discomfort, edema, hot flush, diarrhea, vomiting, cough, hypertension, dyspnea, urinary tract infection, contusion.
Serious Cardiac failure, arrhythmia, hepatotoxicity, hypokalemia, fluid retention.
Postmarketing Non-infectious pneumonitis, myopathy including rhabdomyolysis, fulminant hepatitis including acute hepatic failure, QT prolongation and Torsades de Pointes, anaphylactic reactions.
Pharmacology
Cabazitaxel is a microtubule inhibitor that binds to tubulin and promotes its assembly into microtubules while inhibiting disassembly, leading to stabilization of microtubules and inhibition of mitotic and interphase cellular functions.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits CYP17 (17alpha-hydroxylase/C17,20-lyase), blocking androgen production in testicular, adrenal, and prostatic tumor tissues to suppress androgen-sensitive prostate cancer growth.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Jevtana
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Yonsa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Jevtana
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Yonsa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Jevtana
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Yonsa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JevtanaView full Jevtana profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.